Global pharmaceutical company Merck (NYSE:MRK) will be reporting results this Tuesday before the bell. Here’s what you need ...

Merck will report its earnings on Tuesday, offering insights into how its agreement to lower the price of its diabetes drug ...

Quick Read Merck (MRK) has beaten earnings in 8 consecutive quarters with an average surprise of 5.1%. Ten Merck executives ...

If you are wondering whether Merck’s current share price lines up with its underlying value, you are not alone, and this ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

Merck is expanding its pipeline and portfolio of cardio-pulmonary disease treatments by acquiring Verona Pharma plc. The Rahway pharma giant announced the deal for the biopharmaceutical company ...

In what is shaping up to be a back-loaded month, the FDA is set to release a slew of regulatory decisions in February, ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer. Merck has ...

Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are ...

Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition of UK-based Verona Pharma for ~$10 billion. This move aims to diversify ...

Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases Through this acquisition Merck will add ...

Merck & Co Inc (NYSE:MRK) and Jiangsu Hengrui Pharmaceuticals Co., Ltd on Tuesday entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a), or Lp ...